Resistance to Vitamin D or Parathyroid Hormone
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Endocrine, Gastrointestinal |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Other |
| Healthy: | No |
| Age Range: | 1 - Any |
| Updated: | 1/12/2019 |
| Start Date: | September 29, 1989 |
| Contact: | Lee S Weinstein, M.D. |
| Email: | leew@mail.nih.gov |
| Phone: | (301) 402-2923 |
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
Patients with confirmed or suspected conditions with a resistance to vitamin D or parathyroid
hormone (PTH) will be admitted for diagnosis and treatment, and inclusion in other studies
pertaining to similar conditions.
This study will provide information about problems relating to calcium in the blood, urine,
and bones. Patients in this study will undergo a general evaluation / check-up to give
researchers an idea of each person's condition or disease. Patients will receive treatment
based on their diagnosis and asked to provide specimen samples for further research studies.
hormone (PTH) will be admitted for diagnosis and treatment, and inclusion in other studies
pertaining to similar conditions.
This study will provide information about problems relating to calcium in the blood, urine,
and bones. Patients in this study will undergo a general evaluation / check-up to give
researchers an idea of each person's condition or disease. Patients will receive treatment
based on their diagnosis and asked to provide specimen samples for further research studies.
Patients with confirmed or suspected states with resistance to vitamin D or parathyroid
hormone (PTH) will be admitted for diagnosis and treatment and for inclusion in other
protocols. These states include hypocalcemia, rickets, osteomalacia,
pseudohypoparathyroidism. Resistance to a factor is manifested by deficient bioeffect despite
high levels of the factor in blood. Patients will be tested with multiple indices of mineral
metabolism to establish the diagnosis and examine the spectrum of the underlying disorder.
The principal therapies will be combinations of calcium, phosphate, and a vitamin D analog.
Selected patients will have localization and surgery to remove a tumor that causes renal
wasting of phosphate. Patients will be considered for entry into other research protocols.
hormone (PTH) will be admitted for diagnosis and treatment and for inclusion in other
protocols. These states include hypocalcemia, rickets, osteomalacia,
pseudohypoparathyroidism. Resistance to a factor is manifested by deficient bioeffect despite
high levels of the factor in blood. Patients will be tested with multiple indices of mineral
metabolism to establish the diagnosis and examine the spectrum of the underlying disorder.
The principal therapies will be combinations of calcium, phosphate, and a vitamin D analog.
Selected patients will have localization and surgery to remove a tumor that causes renal
wasting of phosphate. Patients will be considered for entry into other research protocols.
- INCLUSION CRITERIA:
Patients of any age or sex with vitamin D resistance, rickets, osteomalacia,
pseudohypoparathyroidism, pseudo-pseudohypoparathyroidism, or suspicion of these or related
disorders based upon the appropriateness of their problem to ongoing investigations.
Current investigations are focused primarily upon subjects with target tissue resistance to
1,25-dihydroxyvitamin D, pseudohypoparathyroidism, and pseudo-pseudohypoparathyroidism.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 800-411-1222
Click here to add this to my saved trials
